Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNK-225
- Development stage
- Preclinical
- Lead developer
- Synakis
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
SNK-225 is a preclinical-stage therapeutic candidate being developed by Synakis for the treatment of glaucoma. It consists of a small molecule prodrug formulated within a proprietary, injectable, and biodegradable hydrogel delivery system. The platform is designed to provide sustained release of the medication into the eye via affinity-controlled mechanisms, potentially reducing the need for daily eye drops and improving patient compliance. By maintaining a controlled release profile over several months, SNK-225 aims to provide consistent intraocular pressure (IOP) reduction while minimizing the systemic side effects and adherence issues associated with traditional topical therapies.
02
Targets
ADRB1 (β1)ADRB2 (β2)
Beyond the preview
Go deeper on SNK-225.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNK-225.